-
Abstract Number: 824
Results from a Randomized Controlled Trial of the Safety of the Live Varicella Vaccine in TNF-Treated Patients
-
Abstract Number: 825
Systemic Sclerosis Deaths at Younger Ages Have Decreased over the past Five Decades
-
Abstract Number: 826
Immune-Mediated Inflammatory Diseases (IMID) Collectively Rank Among the Leading Causes of Death
-
Abstract Number: 827
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia (FM): Evidence for a Broad Spectrum of Activity on the FM Syndrome
-
Abstract Number: 828
A Path Model Analysis of the Cognitive Determinants of Physical Activity Among Patients with Fibromyalgia (FM)
-
Abstract Number: 829
Dietary Intake Does Not Explain Microbiome Alterations or Symptom Severity in Fibromyalgia
-
Abstract Number: 830
The Efficacy of Non-Pharmacological Interventions for Fibromyalgia: A Systematic Review with Meta-Analysis
-
Abstract Number: 831
Maintaining Musculoskeletal Health: A Randomized Controlled Prevention Trial Amongst People at High Risk of Developing Chronic Widespread Pain
-
Abstract Number: 832
Diagnosis of Fibromyalgia: Comparison of AAPT and ACR Criteria
-
Abstract Number: 833
Effect of a Mobile App to Monitor Patient Reported Outcomes in Rheumatoid Arthritis: A Randomized Controlled Trial
-
Abstract Number: 834
Implementing Patient-Reported Outcome Measures in Clinical Care: Rheumatologist Perspectives on Opportunities and Challenges
-
Abstract Number: 835
High Baseline Patient’s Compared with Evaluator’s Global Assessment Is Associated with Lower Retention and Remission Rates of First TNF Inhibitor in Psoriatic Arthritis Patients – Data from the EuroSpA Research Collaboration Network
-
Abstract Number: 836
Patient-Reported Outcomes from a Randomised, Open-Label, Parallel-Group Study Evaluating Ixekizumab versus Adalimumab in Patients with PsA Who Are Biologic DMARD Naïve: 24-Week Results
-
Abstract Number: 837
Does Discordance Between Baseline Patient’s and Evaluator’s Global Assessment of Disease Activity Impact Retention and Remission Rates of a First TNF Inhibitor in Patients with Axial Spondyloarthritis? Data from the EuroSpA Research Collaboration Network
-
Abstract Number: 838
Are PROMIS Measures Associated with Minimal Disease Activity in Psoriatic Arthritis?
- « Previous Page
- 1
- …
- 56
- 57
- 58
- 59
- 60
- …
- 198
- Next Page »